HOME >> MEDICINE >> NEWS
New drug target might sidestep gleevec resistance, Jefferson scientists show

(PHILADELPHIA) -- Though enormously successful, the leukemia drug Gleevec has some downsides. Recent studies have linked the drug to heart failure in a small number of patients, and drug resistance continues to be a problem. But now, researchers at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia may have found a new way to sidestep such resistance. They have discovered that by reactivating a protein that is normally shut off in leukemia and in Gleevec-resistant cancer cells, leukemia development is halted.

A drug that could turn on the gene that makes the protein C/EBP-alpha, a "transcription factor" required for cells to differentiate, then, might control or even eliminate the cancer.

According to Bruno Calabretta, M.D., Ph.D., professor of cancer biology at Jefferson Medical College of Thomas Jefferson University, transcription factors are molecular switches that turn on genes when their function is needed. C/EBP-alpha expression is low in leukemia cells such as those with the BCR-ABL protein defect, which causes chronic myeloid leukemia (CML), a disease that Gleevec treats so well.

Gleevec is normally prescribed for patients early on in CML, which is characterized by an overabundance of white blood cells. But when the disease advances to the terminal stage, or "blast crisis" phase, the cells, called blasts, remain undifferentiated and accumulate rather than becoming more mature white blood cells called granulocytes. Gleevec is much less effective in this stage, Dr. Calabretta says. Yet, in leukemia cells that respond to treatment with Gleevec, expression of C/EBP-alpha increases.

The researchers looked at what might happen if C/EBP-alpha was turned back on in blast crisis patients and in CML patients who were resistant to Gleevec. Reporting in the journal Blood, they found that in both the laboratory and in mice, immature white blood cells began to differen
'"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
15-Sep-2006


Page: 1 2 3

Related medicine news :

1. NIH scientists target future pandemic strains of H5N1 avian influenza
2. Nottingham center to help UK to meet its carbon targets
3. Wesley Research Institute study targets pharmacists to help diabetes sufferers
4. Dead on target
5. Drug eluting nanostructured coatings enable targeted drug therapy for orthopedic patients
6. New therapeutic targets for neurodegenerative diseases
7. Animal study identifies promising new target for brain tumor therapy
8. Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer
9. New mechanism identified for resistance to targeted lung cancer drugs
10. Head and neck cancer vaccine targets proteins to create immune response
11. New class of HIV drug attacks previously untargeted enzyme

Post Your Comments:
(Date:7/2/2015)... ... ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest location ... The premium frozen yogurt chain was listed as #22 on the Inc. 500 list ... New Albany, MS 38652, will have a grand opening event on July 4, 2015 ...
(Date:7/2/2015)... ... ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest ... the Lone Star State. The premium frozen yogurt chain was listed as #22 on ... opened July 1 at Duke’s Travel Plaza, is located at:, 30176 Hwy 64, Suite ...
(Date:7/2/2015)... ... July 02, 2015 , ... The American Association of ... the Stop Overdose Stat (S.O.S.) Act of 2015 on June 23, 2015. Together ... seeks to decrease drug overdose – especially of heroin and opioid medication – ...
(Date:7/2/2015)... Lincoln, RI (PRWEB) , ... July 02, 2015 , ... ... keep safety in mind. That’s why Amica Insurance is sharing some tips ... Safety Commission (CPSC), approximately 230 people go to the emergency room daily with fireworks-related ...
(Date:7/2/2015)... , ... July 02, 2015 , ... In 2012, Patrick Achebe realized that the gift ... alone. He sat down to write his first poem, and three years later he was ... was special and worth sharing with the world. "I have always believed that the best ...
Breaking Medicine News(10 mins):Health News:sweetfrog Opens First Location in Mississippi 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3Health News:6 Fireworks Safety Tips from Amica Insurance 2Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2
(Date:7/2/2015)... 25, 2015 Research and Markets( http://www.researchandmarkets.com/research/nlfg34/cancer ... by Technology, Imaging and by Application - Forecast to 2020" ... is expected to reach $13.1 Billion in 2020 from an estimated ... The market is dominated by North America ... , and Rest of the World (RoW). The cancer diagnostics ...
(Date:7/2/2015)... Mass. , July 2, 2015   ... and European retinal specialists identify less frequent dosing ... edema (DME), due to the burden on both ... anti-vascular endothelial growth factor (VEGF) injections, which are ... Allergan/Molecular Partners, abicipar pegol, which is in development ...
(Date:7/2/2015)... 2015 BGI gab heute bekannt, ... vom American College of Pathologists (CAP) akkreditiert ... erste klinische Next-Generation-Sequencing Labor, das in ... und somit die höchsten Standards an klinischer ... FDA - 21 CFR Part 11 konformen ...
Breaking Medicine Technology:Global Cancer Diagnostics Market Report 2015 - Technology, Imaging and by Applications Forecasts to 2020 for the $13 Billion Industry 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2
Cached News: